A disease long dismissed as manageable is now revealing a far more serious trajectory — and the therapeutic landscape is shifting rapidly in response. IgA nephropathy, the most common primary glomerulonephritis worldwide, has historically been framed as slow-moving and relatively benign. Emerging registry data are forcing a fundamental reassessment of that assumption, with profound implications for how and when clinicians intervene.

Large-scale registry analyses now indicate that approximately 75% of IgAN patients reach kidney failure within 25 years of diagnosis — a figure strikingly higher than prior estimates that shaped decades of conservative clinical decision-making. Compounding the problem, the average age at kidney biopsy has been rising, suggesting that diagnoses are occurring at more advanced disease stages. This diagnostic lag matters enormously: corticosteroid efficacy appears strongly dependent on residual kidney function at treatment initiation, meaning late biopsies may structurally disadvantage patients before treatment even begins. Established approaches such as renin-angiotensin system blockers and systemic corticosteroids have shown limited capacity to achieve full proteinuria remission. Newer agents — including targeted-release budesonide (which minimizes systemic exposure), SGLT2 inhibitors, and the dual endothelin-angiotensin receptor antagonist sparsentan — demonstrate meaningful proteinuria reduction, though complete remission remains elusive.

This review arrives at a genuinely inflection-point moment for IgAN management. The updated KDIGO guidelines now formally integrate these newer agents, signaling a shift from reactive, damage-control nephrology toward earlier, mechanism-targeted intervention. From a broader nephrology perspective, the IgAN field is benefiting from accelerating understanding of the galactose-deficient IgA1 immunopathogenic cascade, which is enabling complement-targeted and B-cell-directed therapies currently in clinical trials. The key limitation of current evidence remains the absence of long-term randomized data for most newer agents — surrogate endpoints like proteinuria reduction, while promising, have not yet been fully validated as reliable proxies for preserved GFR over decades. For health-conscious adults, the finding most worthy of attention is the magnitude of long-term risk revision: this is not an incremental update but a recalibration that should meaningfully accelerate both biopsy timing and treatment initiation standards globally.